Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...
US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for two new indications for patients with HER2-positive early breast cancer: Cambridge, UK Monday, May 18, 2026, 10:00 H ...
We noticed you're using an ad blocker. We get it: you like to have control of your own internet experience. But advertising revenue helps support our journalism. To read our full stories, please turn ...
Read here latest news, events news, current affairs, recene incidents by Purabi Bora on financialexpress.com . Check here exclusive stories, blogs, bylines, articles written by Purabi Bora on breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results